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T
he accelerated progression of ath-
erosclerosis in diabetes is most
probablytheendresultofthecumu-
lative impact of the major risk factors that
are more prevalent in diabetic subjects,
namely obesity and dyslipidemia, the de-
rangement in carbohydrate metabolism
(hyperglycemic environment, hyperinsu-
linism, and insulin resistance), a pro-
thrombotic tendency, and, perhaps most
important, microalbuminuria and hyper-
tension (1–5). At least two additional car-
diovascularriskfactorsareprobablymore
pronounced in diabetes; they are endo-
thelial dysfunction (6) and an inﬂamma-
tory reaction in the affected blood vessels
mediated by the proinﬂammatory inter-
leukins and expressed by elevated levels
of C-reactive protein (7).
Microalbuminuria is often the ﬁrst
clinical manifestation of early microvas-
cular derangement. In type 2 diabetes, it
isthehallmarkofsubsequentdiabeticne-
phropathy and a surrogate marker of car-
diovascular disease and increased
cardiovascular mortality (8). Further-
more, the presence of microalbuminuria
predictsaworseoutcomeafterpercutane-
ous coronary intervention. The 2-year
mortality after percutaneous coronary in-
tervention in diabetic patients with mi-
croalbuminuria was increased by 85%
compared with individuals with normal
urinary albumin excretion (9). Mi-
croalbuminuria is associated with echo-
cardiographic evidence of left ventricular
hypertrophyandidentiﬁesoverallcardio-
vascular risk also in hypertensive nondi-
abetic patients (10,11). It is therefore
mandatory to screen all diabetic as well as
nondiabetic hypertensive patients for the
presence of microalbuminuria. Indeed,
all the relevant professional associations
have included annual screening for mi-
croalbuminuria in their recommenda-
tions (12,13). Treatment strategies aimed
at reducing urinary albumin excretion
were found to be effective in retarding
theprogressionofrenaldisease,asman-
ifested by prolongation of the time to
doubling of serum creatinine and post-
ponement of end-stage renal disease
and the need to renal replacement ther-
apy (14–17).
Furthermore, the magnitude of early
decline in albuminuria in response to a
giventherapeuticinterventionisareliable
predictor of subsequent renoprotective
effect of this therapy (18).
Intype1diabetes,manypatientswho
initially develop microalbuminuria sub-
sequently revert to normoalbuminuria
(18,19); therefore, the association be-
tween spontaneous or therapy-induced
changesinalbuminexcretionrateandthe
subsequent progression of nephropathy
is less clear (20).
The elucidation of the infrastructure
of the renin-angiotensin-aldosterone sys-
tem and the development of speciﬁc in-
hibitorsofvariousstepsinitsbiochemical
cascade have emerged as the most signif-
icantmeanstocontrolbloodpressure,re-
duce cardiovascular sequelae, and retard
the decline in renal function in all hyper-
tensive patients and especially in diabetic
patients (21,22). The four drug classes
target angiotensin II and aldosterone
through either direct or complimentary
mechanisms. The renin inhibitors reduce
the conversion of angiotensinogen to an-
giotensin I, and ACE inhibitors block the
conversion of angiotensin I to the active
peptide angiotensin II and increase the
availability of bradykinin. Angiotensin-
receptor blockers (ARBs) selectively an-
tagonize angiotensin II at the AT1
receptors and increase the activation of
the AT2 receptors. Finally, the aldoste-
rone-receptor blockers reduce the meta-
bolic and the proliferative effects of
aldosterone (Fig. 1).
When appropriate dosage was used,
long-term studies in hypertensive and in
diabetic patients could demonstrate little
if any difference in blood pressure lower-
ingandinthecardiovascularaswellasthe
renoprotective efﬁcacy between the vari-
ous renin-angiotensin-aldosterone sys-
teminhibitingorblockingagents(23,24);
there may, in fact, be a small advantage of
ACEinhibitorsoverARBs,atleastasfaras
cardiovascular protection is considered
(25). There is little doubt that the major
predictivefactorofsubsequentcardiovas-
cular as well as kidney protection is the
degree of blood pressure lowering (26–
30).Controlofhypertensionis,therefore,
paramount to postpone or possibly pre-
vent end-stage renal disease and cardio-
vascular complications.
Thecomplexityoftherenin-angiotensin-
aldosteronesystemandtheprovenefﬁcacy
of the various blocking and inhibiting
agents stimulated the design of clinical
trials to test the hypothesis that, in such a
complex system, combining the effect of
twoormoredrugsmayofferbetterresults
than a single intervention. Diabetic ne-
phropathy was the natural choice as the
researchplatformbecauseofthehigh-risk
proﬁle of these patients, the well-known
downhill clinical course all the way to
end-stagekidney,and,therefore,theabil-
ity to clearly deﬁne and demonstrate the
efﬁcacy of therapeutic interventions. In a
high-risk model, any therapeutic effect is
augmented and may be later applicable in
other lower-risk constellations. Abe et
al. (31) in Japan examined the renopro-
tective effect of the addition of an ARB
(losartan) or an ACE inhibitor to conven-
tional antihypertensive regimens or to
ACE inhibitor–based regimens in pa-
tients with diabetic nephropathy. The
drug doses were titrated to obtain prede-
termined blood pressure reduction goals.
They found no advantage of dual renin-
angiotensin system (RAS) blockade over
the combination of a single RAS blocker
with conventional antihypertensive regi-
mens. These results corroborate the con-
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hypertensive patients (32) where, after
3.2 years’ follow-up, candesartan-based
regimens rendered equipotent cardiovas-
cular and renal protection to amlodipine-
based regimens. In a rather short-term
20-week study, the IMPROVE investiga-
tors found no advantage of dual RAS
blockade with irbesartan and ramipril
over ramipril alone in reducing albumin-
uria in high-risk hypertensive subjects
(33).
So far, the largest and best controlled
studythatcomparedtheantihypertensive
effect and cardiovascular and renal pro-
tection in high-risk hypertensive and dia-
betic patients was the ONTARGET trial
(24). In this prospective study, 25,000
patients were randomized to antihyper-
tensive treatment protocols based on an
ARB (telmisartan), an ACE inhibitor
(ramipril), or the combination of both.
After a mean follow-up period of 56
months, telmisartan was equivalent to
ramipril in all aspects (albeit with a better
side-effect proﬁle). The combination of
the two drugs was associated with more
adverse events without an increase in
beneﬁt.
The results of ﬁve parallel-group
studiesand16crossoverstudiescompris-
ing together 654 patients and comparing
dual RAS blockade with ARBs and ACE
inhibitors to either agent alone were
pulled together by MacKinnon et al. (34).
Theyconcludedthatthedualtherapywas
safeinpatientswithproteinuricrenaldis-
ease. The dual blockade was associated
withaminorincreaseinserumpotassium
and a small decline in glomerular ﬁltra-
tion rate, as compared with each of the
single agents. Also, the combination ther-
apy was associated with a signiﬁcant fur-
ther decrease in proteinuria in diabetic as
well as nondiabetic patients. Deﬁnite end
points of renoprotection could not be as-
sessedinthisanalysisbecauseofthesmall
number of patients and the short fol-
low-up period. Kunz et al. (35) extracted,
in hitherto the largest meta-analysis, the
results of 110 studies in which the effect
of either an ACE inhibitor or an ARB on
proteinuria in renal disease was com-
pared with the combination of the two
agents. All the studies were short-lived
and comprised together 6,181 patients.
In 72 studies, the follow-up periods were
only 1–4 months, whereas in the remain-
ing 38 studies, the follow-up lasted 5–12
months.Asexpected,bothARBsandACE
inhibitors reduced proteinuria compared
withplaceboorcalcium-channelblockers
and were equipotent when compared
with each other. The combination of
ARBs and ACE inhibitors further reduced
proteinuria more than either agent alone.
The ratio of means for combination ther-
apyversusARBswas0.76(CI0.68–0.85)
over 1–4 months and 0.75 (CI 0.61–
0.92) over 5–12 months. For combina-
tion therapy versus ACE inhibitors, the
ratio of means was 0.78 (CI 0.72–0.84)
over 1–4 months and 0.82 (CI 0.67–
1.01) over 5–12 months (Table 1). The
studies included in the meta-analysis
were small, of short duration, and of vari-
able quality. Therefore, the uncertainty
regarding the important end points,
mainly preservation of kidney function
and cardiovascular protection, could not
be resolved. Also, the issues of possible
preponderance of adverse effects of the
dual therapy and the stability of the ther-
apeutic effect over time remained unde-
cided, thus limiting the applicability of
the results to clinical practice.
The theoretical added beneﬁt of dou-
ble renin-angiotensin-aldosterone system
blockade was further explored using the
remaining drug classes, namely aldoste-
rone receptor antagonists and the new re-
nin inhibitor aliskiren. Based on the well-
known observation of the aldosterone-
escape phenomenon under single RAS
blockade with either an ACE inhibitor or
an ARB (36), Schjoedt et al. (37) exam-
ined the effect of spironolactone as an
add-on agent to other RAS blockers on
nephritic-range albuminuria in patients
with diabetic nephropathy. The addition
of low-dose (25 mg) spironolactone re-
sulted in a further decline of 32% in albu-
min excretion rate. The short 2-month
duration of this study precludes any con-
clusions as to renoprotection. A recent
systematic review (38) suggested that
adding aldosterone blockers to ACE in-
hibitors or to ARBs signiﬁcantly reduced
albuminuria. The long-term safety of this
regimen cannot be determined however.
The novel renin inhibitor aliskiren
was tested, both alone or in combination
with ACE inhibitors, in animal models of
diabetic nephropathy and in short-term
clinical studies on hypertensive subjects
(39,40). This agent is probably equipo-
tent to the other major drugs in lowering
blood pressure and in reducing protein-
Figure 1—The renin-angiotensin-aldosterone cascade and the various options to block the sys-
tem. AI, angiotensin I; AII, angiotensin II.
Table 1—ACE inhibitors and ARBs: compar-
ative effect on proteinuria in parallel-group
randomized studies of 5–12 months’ dura-
tion: a meta-analysis
Risk ratio
(95% CI)
ARBs vs. placebo 0.66 (0.63–0.69)
ARBs vs. ACE inhibitors 1.08 (0.96–1.22)
ARBs vs. calcium-channel
blockers 0.62 (0.55–0.70)
ARBs  ACE inhibitors
vs. ARBs 0.75 (0.61–0.92)
ARBs  ACE inhibitors
vs. ACE inhibitors 0.82 (0.67–1.01)
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ies that would permit a discussion on
clinically relevant effects.
Management of hypertension is, no
doubt, the most signiﬁcant intervention
inpreventingdiabeticrenalaswellascar-
diovascular disease. Tight control of
blood pressure to recommended target
levels affords long-term complication-
free periods for diabetic patients. There
seems to be a wide consensus that RAS
blocking agents offer better renal protec-
tion than other drugs with equivalent an-
tihypertensive potency. However, despite
numerous studies, there is no real evidence
thatusingdoubleblockadeoffersanadvan-
tage in clinically relevant end points over
thealreadytime-honoredsingleRASblock-
ade in combination with thiazide diuretics
and calcium channel blockers.
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